LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

LLY

766.38

+2.78%↑

JNJ

177.06

-0.18%↓

ABBV

216.94

+1.09%↑

UNH

342.77

-1.67%↓

AZN

77.82

+0.31%↑

Search

Design Therapeutics Inc

Ouvert

5.91 -0.34

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.61

Max

6.05

Chiffres clés

By Trading Economics

Revenu

-1.4M

-19M

Marge bénéficiaire

-2,321.599

Employés

57

EBITDA

-1.3M

-22M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-14.68% downside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

107M

331M

Ouverture précédente

6.25

Clôture précédente

5.91

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Design Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 sept. 2025, 22:39 UTC

Acquisitions, Fusions, Rachats

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept. 2025, 16:43 UTC

Principaux Mouvements du Marché

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept. 2025, 16:42 UTC

Principaux Mouvements du Marché

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept. 2025, 16:35 UTC

Principaux Mouvements du Marché

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept. 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept. 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

CSL Expects Commercial Launch in 2029

15 sept. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept. 2025, 21:16 UTC

Acquisitions, Fusions, Rachats

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept. 2025, 21:15 UTC

Acquisitions, Fusions, Rachats

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept. 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sept. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept. 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept. 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 sept. 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept. 2025, 17:50 UTC

Acquisitions, Fusions, Rachats

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept. 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept. 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

Comparaison

Variation de prix

Design Therapeutics Inc prévision

Objectif de Prix

By TipRanks

-14.68% baisse

Prévisions sur 12 Mois

Moyen 5 USD  -14.68%

Haut 5 USD

Bas 5 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

2 ratings

0

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

3.26 / 3.63Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat